Skip to content

Use of Steroids for postoperative keratoplasty for fungal keratities

To compare the outcome of therapeutic penetrating keratoplasty for fungal keratitis with late vs immediate postoperative addition of topical corticosteroids.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/06/043019
Enrollment
176
Registered
2022-06-06
Start date
Unknown
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H160- Corneal ulcer

Interventions

Intervention1: Topical corticosteroids: Topical corticosteroids will be added along with the anfungus first day after the transplant done for fungal keratities. Both the groups will receive topical Na

Sponsors

L V Prasad Eye Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Cases with microbiologically confirmed fungal keratitis undergoing therapeutic keratoplasty for worsening of infection. 2.Size of infiltrate less or equal to 10 mm. 3.Intraoperative no evidence of residual infection 4.Immediate Post operative anterior chamber formed and no clinical evidence of infection 5.Use of MK medium corneal tissue of any grade with or with out intact epithelium 6.Intraoperative Preserved lens 7.Ready to give consent 8.Consent for regular follow-up 9.More than 18 years 10.Surgery performed by surgeons with experience of performing more than 20 TPK.

Exclusion criteria

Exclusion criteria: 1.Any evidence of intraop or clinical post-operative infection 2.Size of infiltrate > 10 mm 3.Not willing to come for regular follow-up or admission or giving consent 4.Disorganized anterior chamber 5.Posterior segment involvement as confirmed on Echoes in the posterior segment on B scan 6.Intraoperative presence of retero-iris and lens exudates. 7.Presence if corneal perforation before the surgery 8.Presence of uncontrolled diabetes or any other cause of decreased imununity.

Design outcomes

Primary

MeasureTime frame
Graft survival rate at 6 months in both the groups and compared.Timepoint: 3, 7,14, 30 days, 3 , 6 months and 1 year of follow-up

Secondary

MeasureTime frame
Number of patients having recurrence of similar infection with in 2 weeks of surgery.Timepoint: 3, 7,14, 30 days, 3 , 6 months and 1 year of follow-up

Countries

India

Contacts

Public ContactDrBhupesh Bagga

L V Prasad Eye Institute

bhupesh@lvpei.org04068102615

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026